Technical analysis of Aprea Therapeutics, Inc. (APRE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
Price Performance
| 1 month | +11.43% |
| 3 months | +4.73% |
| Year-to-date | -12.22% |
| 1 year | -50.08% |
| 3 years | -81.78% |
| 5 years | -99.26% |
52-Week Range
| 52-week High | $1.69 |
| 52-week Low | $0.55 |
| Avg Volume (90d) | 216K |
Technical Indicators
| SMA 50 | $0.72 |
| SMA 200 | $0.81 |
| Beta | 1.57 |
| 30-day Volatility (annualised) | 99.3% |
| Price vs SMA 50 | +4.4% |
| Price vs SMA 200 | -7.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.40 | |
| 2025-11 | $1.26 | -10.0% |
| 2025-12 | $0.85 | -32.3% |
| 2026-01 | $0.80 | -6.7% |
| 2026-02 | $0.92 | +15.2% |
| 2026-03 | $0.76 | -16.8% |
| 2026-04 | $0.80 | +4.8% |
| 2026-05 | $0.89 | +11.6% |
| 2026-06 | $0.80 | -10.1% |
| 2026-07 | $0.62 | -22.7% |
| 2026-08 | $0.80 | +29.0% |
| 2026-09 | $0.75 | -6.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $0.73 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.63 |